One To Watch

Aquestive Therapeutics

A specialty pharmaceutical company headquartered in Warren, New Jersey. The company develops and commercializes medicines using oral film drug delivery, with commercial activities primarily in the United States and selected international markets through partners.

Founding and History

Founded in 2004, Aquestive is publicly traded on Nasdaq (AQST). The company built its business around oral film formulation and manufacturing capabilities and has expanded into a model combining proprietary product development with partner-supported commercial products.

Therapy Areas and Focus

Aquestive’s proprietary development focus is concentrated in:

CNS/neurology, particularly seizure rescue
Allergy/immunology, focused on emergency treatment of anaphylaxis
The company also participates in additional therapeutic areas through licensed products and manufacturing relationships.

Technology Platforms and Modalities

Aquestive’s core platform is PharmFilm, a proprietary oral film drug delivery technology designed for buccal or sublingual administration. The platform is used to develop products intended to be:

portable and easy to administer
suitable for rapid-onset “rescue” use cases
needle-free alternatives where injections create barriers to access or use

The technology is positioned for settings where caregivers or patients need to administer treatment quickly and reliably outside clinical facilities.

Strategic Partnerships

Aquestive operates a mixed commercial model that includes proprietary products, licensing, and collaborations. The company generates revenue both from its own products and from partner programs where it serves as developer and/or manufacturer.

FAQ Section

Aquestive develops and commercializes medicines delivered via oral film. Its PharmFilm platform is designed to deliver drugs through the oral mucosa (buccal or sublingual), supporting formulations intended for ease of use and rapid administration.

The company’s proprietary pipeline is centered on acute and episodic indications in neurology (seizure rescue) and allergy/immunology (anaphylaxis). Additional products outside these areas are largely partner-linked.

Aquestive markets oral film products in neurology and continues to expand its rescue-medicine franchise. Its late-stage pipeline includes a sublingual epinephrine oral film candidate intended as a needle-free alternative for emergency treatment of severe allergic reactions, including anaphylaxis.

Recent company developments have focused on expanding access and market coverage for its seizure rescue franchise and advancing its epinephrine oral film program through the U.S. regulatory pathway.

Clinical evidence disclosed by the company has emphasized pharmacokinetic comparability and usability in acute settings, particularly for its epinephrine oral film candidate, reflecting the need to demonstrate reliable delivery and rapid exposure consistent with emergency use.

Key milestones include continued commercialization and label/access expansion for marketed products and regulatory progress for the epinephrine oral film program. The company’s near-term trajectory is closely linked to FDA outcomes and launch readiness for its next proprietary product.

Oral film is positioned as a delivery format that can simplify administration, improve portability, and reduce reliance on injections or swallowing pills—features that are particularly relevant in emergency settings where speed and ease of use are critical.

Want to Update your Company's Profile?